Nu Skin Enterprises, Inc. (NYSE: NUS) closed the day trading at $12.83 down -2.80% from the previous closing price of $13.20. In other words, the price has decreased by -$0.37 from its previous closing price. On the day, 984636 shares were traded.
Ratios:
For a better understanding of NUS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.54. For the most recent quarter (mrq), Quick Ratio is recorded 1.25 and its Current Ratio is at 2.10. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on January 31, 2023, Downgraded its rating to Hold and sets its target price to $39 from $43 previously.
BofA Securities Upgraded its Underperform to Neutral on October 02, 2020, whereas the target price for the stock was revised from $54 to $58.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 26 ’24 when LIPMAN ANDREW D sold 2,000 shares for $12.46 per share. The transaction valued at 24,920 led to the insider holds 29,225 shares of the business.
LIPMAN ANDREW D sold 2,000 shares of NUS for $37,100 on Jan 25 ’24. The Director now owns 31,225 shares after completing the transaction at $18.55 per share. On Dec 26 ’23, another insider, LIPMAN ANDREW D, who serves as the Director of the company, sold 2,000 shares for $19.39 each. As a result, the insider received 38,780 and left with 33,225 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUS now has a Market Capitalization of 634.07M and an Enterprise Value of 973.58M. As of this moment, Nu’s Price-to-Earnings (P/E) ratio for their current fiscal year is 75.78, and their Forward P/E ratio for the next fiscal year is 8.64. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 11.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.32 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at 0.49 whereas that against EBITDA is 7.01.
Stock Price History:
Over the past 52 weeks, NUS has reached a high of $41.50, while it has fallen to a 52-week low of $12.06. The 50-Day Moving Average of the stock is 16.06, while the 200-Day Moving Average is calculated to be 21.97.
Shares Statistics:
Over the past 3-months, NUS traded about 807.09K shares per day on average, while over the past 10 days, NUS traded about 788.35k shares per day. A total of 49.50M shares are outstanding, with a floating share count of 48.21M. Insiders hold about 2.45% of the company’s shares, while institutions hold 84.24% stake in the company. Shares short for NUS as of Feb 29, 2024 were 2.04M with a Short Ratio of 2.52, compared to 2.37M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.12% and a Short% of Float of 7.64%.
Dividends & Splits
NUS’s forward annual dividend rate is 1.23, up from 1.56 a year ago. Against a Trailing Annual Dividend Yield of 11.82%, it implies a Forward Annual Dividend Yield of 1.87%. The stock’s 5-year Average Dividend Yield is 4.15.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.05 and a low estimate of $0.05, while EPS last year was $0.37. The consensus estimate for the next quarter is $0.34, with high estimates of $0.37 and low estimates of $0.32.
Analysts are recommending an EPS of between $1.15 and $1.12 for the fiscal current year, implying an average EPS of $1.14. EPS for the following year is $1.55, with 3 analysts recommending between $1.69 and $1.39.
Revenue Estimates
3 analysts predict $426.56M in revenue for the current quarter. It ranges from a high estimate of $434.14M to a low estimate of $414.96M. As of the current estimate, Nu Skin Enterprises, Inc.’s year-ago sales were $477.48M, an estimated decrease of -10.70% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $453.02M, a decrease of -11.00% less than the figure of -$10.70% in the same quarter last year. There is a high estimate of $458.32M for the next quarter, whereas the lowest estimate is $450.34M.
A total of 3 analysts have provided revenue estimates for NUS’s current fiscal year. The highest revenue estimate was $1.82B, while the lowest revenue estimate was $1.81B, resulting in an average revenue estimate of $1.81B. In the same quarter a year ago, actual revenue was $1.97B, down -7.90% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $1.87B in the next fiscal year. The high estimate is $1.89B and the low estimate is $1.84B. The average revenue growth estimate for next year is up 3.10% from the average revenue estimate for this year.
